Latest Astellas Pharma Inc. Stories
SANTA MONICA, Calif., Sept. 1 /PRNewswire/ -- Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing. "Despite the availability of several therapies for the treatment...
SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Recent Highlights: Qutenza launched in April 2010Qutenza available and/or on formulary at 60 U.S. hospitals Astellas initiates Qutenza E.U. launch in Germany, Austria, and the UK Completed $40 million royalty based debt financingUpcoming 2010 Milestones: Qutenza launch in additional E.U. markets by Astellas Initiation of Phase 2 clinical trial of NGX-1998 in PHN patientsNeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on...
TARRYTOWN, N.Y. and TOKYO, July 28 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. ("Regeneron"; Nasdaq: REGN) and Astellas Pharma Inc. ("Astellas"; Headquarters: Tokyo, Japan; President & CEO: Masafumi Nogimori) announced today that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates....
TARRYTOWN, N.Y., July 28 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009. The Company reported a net loss of $56.0 million, or $0.69 per share (basic and...
TOKYO, June 28 /PRNewswire/ -- Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori, "Astellas") announced that the company presented results from a Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor, at the 70th Scientific Sessions of the American Diabetes Association (ADA) on June 26, 2010 (EST). ASP1941 is designed to block the re-absorption of glucose in the kidney and excrete glucose in the urine. The oral presentation, along with...
TOKYO, June 9 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) for $4.0 billion. Masafumi Nogimori, President and CEO of Astellas said, "We are delighted to announce the completion of this transaction with OSI. We are truly excited by the opportunities that the combination will provide and we look forward to working with our new colleagues at OSI. This compelling transaction marks an...
TOKYO, June 8 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today the completion of its tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc. (Nasdaq: OSIP). The subsequent offer period announced by Astellas on June 3 expired at 12:00 midnight, New York City time, on June 7, 2010. Computershare Trust Company, N.A., the depositary for the tender offer, has advised that, as of the expiration of the subsequent offer period, a total of 57,232,357...
CHICAGO, June 7 /PRNewswire/ -- If an average day begins as a hectic race to get the kids off to school and get to work on time, imagine starting that day with a migraine. For many of the nation's 30 million migraine sufferers whose lives are often turned upside down by their migraines, relief can't come soon enough. In a new survey released today by the National Headache Foundation (NHF), 3 in 4 migraine sufferers said their current medication doesn't work fast enough to get them back to...
TOKYO, June 3 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today the completion of the initial tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc. (Nasdaq: OSIP). The initial offer period expired at 12:00 midnight, New York City time, on June 2, 2010. Computershare Trust Company, N.A., the depositary for the tender offer, has advised that a total of 48,415,727 shares were validly tendered and not withdrawn prior to the expiration of the initial...
GENEVA, May 20, 2010 /PRNewswire/ -- - Expert Tips for Parents of Children With Eczema Several leading European dermatologists have today launched guidance to help parents reduce the burden of eczema on children living with this disease. Experts from Denmark, France, Germany, Poland and Spain have come together to agree a consensus of 'top tips', which focus on avoiding situations that trigger painful flares and different ways to increase eczema 'flare-free' periods. The 'top...
